Monocytes expressing CX3CR1 orchestrate the development of vincristine-induced pain

Journal of Clinical Investigation

Volumn 124, Issue 5, 2014, Pages 2023-2036

  Old, Elizabeth A ^a   Nadkarni, Suchita ^b   Grist, John ^a   Gentry, Clive ^a   Bevan, Stuart ^a   Kim, Ki Wook ^c   Mogg, Adrian J ^d   Perretti, Mauro ^b   Malcangio, Marzia ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM10 ENDOPEPTIDASE; CATHEPSIN S; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR2 ANTAGONIST; FRACTALKINE; INTERCELLULAR ADHESION MOLECULE 1; REACTIVE OXYGEN METABOLITE; TRANSIENT RECEPTOR POTENTIAL CHANNEL A1; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; VASCULAR CELL ADHESION MOLECULE 1; VINCRISTINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER PAIN; CHEMOTHERAPY INDUCED PAIN; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; LEUKOCYTE ADHERENCE; MACROPHAGE ACTIVATION; MALE; MICROGLIA; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN TARGETING; SCIATIC NERVE; SPINAL CORD DORSAL HORN; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHEMOKINE CX3CL1; GENE EXPRESSION REGULATION; HYPERALGESIA; MICE; MICE, KNOCKOUT; MONOCYTES; PAIN; RECEPTORS, CHEMOKINE; VINCRISTINE;

EID: 84899705648     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI71389     Document Type: Article

References (50)

1. Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst. 2008;13(1):27-46.
2. Balayssac D, et al. Patterns of P-glycoprotein activity in the nervous system during vincristine-induced neuropathy in rats. J Peripher Nerv Syst. 2005; 10(3):301-310.
3. Kim BJ, et al. Chemotherapy-related polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma. Qual Life Res. 2010;19(8):1097-1103.
4. Dougherty PM, Cata JP, Cordella JV, Burton A, Weng HR. Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain. 2004;109(1-2):132-142.
5. Bennett BK, Park SB, Lin CS, Friedlander ML, Kiernan MC, Goldstein D. Impact of oxaliplatin-induced neuropathy: a patient perspective. Support Care Cancer. 2012;20(11):2959-2967.
6. Dougherty PM, Cata JP, Burton AW, Vu K, Weng HR. Dysfunction in multiple primary afferent fiber subtypes revealed by quantitative sensory testing in patients with chronic vincristine-induced pain. J Pain Symptom Manage. 2007;33(2):166-179.
7. Authier N, et al. Animal models of chemother- apy-evoked painful peripheral neuropathies. Neurotherapeutics. 2009;6(4):620-629.
8. Geis C, Beyreuther BK, Stohr T, Sommer C. Lacosamide has protective disease modifying properties in experimental vincristine neuropathy. Neuropharmacology. 2011;61(4):600-607.
9. Flatters SJ, Bennett GJ. Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. Pain. 2004;109(1-2):150-161.
10. Peters CM, et al. Intravenous paclitaxel administration in the rat induces a peripheral sensory neuropathy characterized by macrophage infiltration and injury to sensory neurons and their supporting cells. Exp Neurol. 2007;203(1):42-54.
11. Hansen N, et al. Serotonin transporter deficiency protects mice from mechanical allodynia and heat hyperalgesia in vincristine neuropathy. Neurosci Lett. 2011;495(2):93-97.
12. Kiguchi N, Maeda T, Kobayashi Y, Kondo T, Ozaki M, Kishioka S. The critical role of invading peripheral macrophage-derived interleukin-6 in vincristine- induced mechanical allodynia in mice. Eur J Pharmacol. 2008;592(1-3):87-92.
13. Uceyler N, et al. Heterozygous P0 deficiency protects mice from vincristine-induced polyneuropathy. J Neurosci Res. 2006;84(1):37-46.
14. Xiao WH, Zheng H, Bennett GJ. Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel. Neuroscience. 2012;203:194-206.
15. Aapro MS, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006;42(15):2433-2453.
16. Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol. 2009;27:119-145.
17. Zheng FY, Xiao WH, Bennett GJ. The response of spinal microglia to chemotherapy-evoked painful peripheral neuropathies is distinct from that evoked by traumatic nerve injuries. Neuroscience. 2011;176:447-454.
18. Zhang H, Yoon SY, Zhang H, Dougherty PM. Evidence that spinal astrocytes but not microglia contribute to the pathogenesis of Paclitaxel-induced painful neuropathy. J Pain. 2012;13(3):293-303.
19. Barclay J, et al. Role of the cysteine protease cathepsin S in neuropathic hyperalgesia. Pain. 2007; 130(3):225-234.
20. Auffray C, et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science. 2007;317(5838):666-670.
21. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity. 2003;19(1):71-82.
22. Yona S, et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity. 2013;38(1):79-91.
23. Landsman L, et al. CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood. 2009;113(4):963-972.
24. Schwarz N, et al. Requirements for leukocyte transmigration via the transmembrane chemokine CX3CL1. Cell Mol Life Sci. 2010;67(24):4233-4248.
25. Staniland AA, et al. Reduced inflammatory and neuropathic pain and decreased spinal microglial response in fractalkine receptor (CX3CR1) knockout mice. J Neurochem. 2010;114(4):1143-1157.
26. Michaelis M, et al. Chemotherapy-associated angiogenesis in neuroblastoma tumors. Am J Pathol. 2012;180(4):1370-1377.
27. Schenkel AR, Mamdouh Z, Muller WA. Locomotion of monocytes on endothelium is a critical step during extravasation. Nat Immunol. 2004;5(4):393-400.
28. Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. Nat Rev Immunol. 2011;11(11):762-774.
29. White GE, Iqbal AJ, Greaves DR. CC chemokine receptors and chronic inflammation - therapeutic opportunities and pharmacological challenges. Pharmacol Rev. 2013;65(1):47-89.
30. Mamdouh Z, Chen X, Pierini LM, Maxfield FR, Muller WA. Targeted recycling of PECAM from endothelial surface-connected compartments during diapedesis. Nature. 2003;421(6924):748-753.
31. Kim KW, et al. In vivo structure/function and expression analysis of the CX3C chemokine fractalkine. Blood. 2011;118(22):e156-e167.
32. Clark AK, et al. Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain. Proc Natl Acad Sci U S A. 2007;104(25):10655- 10660.
33. Andersson DA, Gentry C, Moss S, Bevan S. Transient receptor potential A1 is a sensory receptor for multiple products of oxidative stress. J Neurosci. 2008;28(10):2485-2494.
34. Dai Y, et al. Sensitization of TRPA1 by PAR2 contributes to the sensation of inflammatory pain. J Clin Invest. 2007;117(7):1979-1987.
35. Obata K, et al. TRPA1 induced in sensory neurons contributes to cold hyperalgesia after inflammation and nerve injury. J Clin Invest. 2005;115(9):2393-2401.
36. Trevisan G, et al. Novel therapeutic strategy to prevent chemotherapy-induced persistent sensory neuropathy by TRPA1 blockade. Cancer Res. 2013;73(10):3120-3131.
37. Chen Y, Yang C, Wang ZJ. Proteinase-activated receptor 2 sensitizes transient receptor potential vanilloid 1, transient receptor potential vanilloid 4, and transient receptor potential ankyrin 1 in paclitaxel-induced neuropathic pain. Neuroscience. 2011;193:440-451.
38. Barriere DA, et al. Paclitaxel therapy potentiates cold hyperalgesia in streptozotocin-induced diabetic rats through enhanced mitochondrial reactive oxygen species production and TRPA1 sensitization. Pain. 2012;153(3):553-561.
39. Docherty RJ, Ginsberg L, Jadoon S, Orrell RW, Bhattacharjee A. TRPA1 insensitivity of human sural nerve axons after exposure to lidocaine. Pain. 2013;154(9):1569-1577.
40. Weller K, Reeh PW, Sauer SK. TRPV1, TRPA1, and CB1 in the isolated vagus nerve - axonal chemosensitivity and control of neuropeptide release. Neuropeptides. 2011;45(6):391-400.
41. Anand U, et al. TRPA1 receptor localisation in the human peripheral nervous sytem and functional studies in cultured human and rat sensory neurons. Neurosci Lett. 2008;438(2):221-227.
42. Balayssac D, et al. Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence. Expert Opin Drug Saf. 2011;10(3):407-417.
43. Alessandri-Haber N, Dina OA, Joseph EK, Reichling DB, Levine JD. Interaction of transient receptor potential vanilloid 4, integrin, and SRC tyrosine kinase in mechanical hyperalgesia. J Neurosci. 2008;28(5):1046-1057.
44. Flatters SJ, Bennett GJ. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain. 2006;122(3):245-257.
45. Karlstrom S, et al. Substituted 7-amino-5-thiothiazolo[ 4,5-d]pyrimidines as potent and selective antagonists of the fractalkine receptor (CX3CR1). J Med Chem. 2013;56(8):3177-3190.
46. Niess JH, et al. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science. 2005;307(5707):254-258.
47. Medina-Contreras O, et al. CX3CR1 regulates intestinal macrophage homeostasis, bacterial translocation, and colitogenic Th17 responses in mice. J Clin Invest. 2011;121(12):4787-4795.
48. Combadiere C, et al. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation. 2003;107(7):1009- 1016.
49. Jung S, et al. Analysis of fractalkine receptor CX(3) CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol. 2000;20(11):4106-4114.
50. Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods. 1994;174(1-2):83-93.